End-of-day quote
Nasdaq
06:00:00 2024-05-22 pm EDT
|
5-day change
|
1st Jan Change
|
21.77
USD
|
-5.55%
|
|
-14.49%
|
+109.33%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
154.1
|
661.8
|
-
|
-
|
Enterprise Value (EV)
1 |
154.1
|
348.3
|
143.3
|
661.8
|
P/E ratio
|
-1.23
x
|
-10.3
x
|
-8.67
x
|
-6.93
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
54.5
x
|
363
x
|
335
x
|
244
x
|
EV / Revenue
|
54.5
x
|
191
x
|
72.5
x
|
244
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-4.47
x
|
-1.67
x
|
-6.74
x
|
FCF Yield
|
-
|
-22.4%
|
-59.8%
|
-14.8%
|
Price to Book
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
14,818
|
29,349
|
-
|
-
|
Reference price
2 |
10.40
|
22.55
|
22.55
|
22.55
|
Announcement Date
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
2.826
|
1.824
|
1.977
|
2.707
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-48.17
|
-77.53
|
-97.8
|
-130
|
Operating Margin
|
-
|
-1,704.67%
|
-4,251.55%
|
-4,945.61%
|
-4,802.42%
|
Earnings before Tax (EBT)
1 |
-
|
-43.56
|
-63.65
|
-88.36
|
-120.8
|
Net income
1 |
-28.48
|
-43.56
|
-63.65
|
-88.36
|
-120.8
|
Net margin
|
-
|
-1,541.22%
|
-3,490.48%
|
-4,468.65%
|
-4,462.44%
|
EPS
2 |
-7.100
|
-8.450
|
-2.193
|
-2.601
|
-3.252
|
Free Cash Flow
1 |
-
|
-
|
-78
|
-85.74
|
-98.21
|
FCF margin
|
-
|
-
|
-4,277.09%
|
-4,335.68%
|
-3,627.88%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/1/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.924
|
0.457
|
0.874
|
0.3137
|
0.3137
|
0.3137
|
0.319
|
0.319
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-15.76
|
-12.96
|
-17.84
|
-18.56
|
-19.88
|
-21.26
|
-18.91
|
-19.77
|
Operating Margin
|
-1,705.52%
|
-2,835.01%
|
-2,041.65%
|
-5,917.74%
|
-6,338.14%
|
-6,778.46%
|
-5,927.43%
|
-6,197.34%
|
Earnings before Tax (EBT)
1 |
-14.76
|
-10.56
|
-13.75
|
-14.95
|
-16.33
|
-18.64
|
-15.63
|
-16.58
|
Net income
1 |
-14.76
|
-10.56
|
-13.75
|
-14.95
|
-16.33
|
-18.64
|
-15.63
|
-16.58
|
Net margin
|
-1,597.73%
|
-2,311.38%
|
-1,573%
|
-4,766.47%
|
-5,206.43%
|
-5,942.76%
|
-4,898.43%
|
-5,198.75%
|
EPS
2 |
-3.780
|
-
|
-0.5400
|
-0.5317
|
-0.5767
|
-0.6317
|
-0.5500
|
-0.6033
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/23
|
3/21/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
314
|
519
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-78
|
-85.7
|
-98.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
0.13
|
0.18
|
0.21
|
Capex / Sales
|
-
|
-
|
7.02%
|
9.31%
|
7.7%
|
Announcement Date
|
8/1/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
21.92
USD Average target price
49.29
USD Spread / Average Target +124.84% Consensus |
1st Jan change
|
Capi.
|
---|
| +109.33% | 662M | | +9.83% | 118B | | +10.80% | 106B | | -10.84% | 23.4B | | -1.69% | 22.1B | | -10.23% | 18.34B | | -41.92% | 16.59B | | -15.11% | 15.97B | | +6.62% | 14.03B | | +17.53% | 11.67B |
Bio Therapeutic Drugs
|